The shelf registration signals a high likelihood of near-term equity issuance to fund ongoing clinical trials. With only ~2.6 quarters of cash at current burn, a follow-on offering is probable within months. Traders should watch for a prospectus supplement detailing actual terms and size of any takedown.
Price Chart
Executive Summary
Forte Biosciences filed Amendment No. 1 to its S-3 shelf registration statement, registering up to $500M in securities (common, preferred, debt, warrants, etc.). The company is a clinical-stage biopharma with no revenue, burning ~$22M/quarter, and had $58.2M cash as of March 31, 2026. The shelf enables future capital raises, likely to fund Phase 2 celiac and other trials.
Key Financial Metrics
Key Facts
- Shelf registration of up to $500,000,000 in securities (common, preferred, debt, warrants, units)
- Pre-revenue clinical-stage biopharma with net loss of $22.1M in Q1 2026 vs $15.7M in Q1 2025
- Cash and cash equivalents of $58.2M as of March 31, 2026, down from $77.0M at Dec 31, 2025
- Operating cash burn of ~$22.4M/quarter; at current burn rate, cash runway extends ~2.6 quarters
- Lead candidate FB102 in Phase 2 celiac study (topline expected 2026), Phase 1b vitiligo and alopecia areata
- Market cap of $338M; shelf size of $500M is ~148% of current market cap, representing massive potential dilution
Financial Impact
Shelf registration of up to $500M, representing ~148% of current $338M market cap. Q1 2026 net loss of $22.1M, cash burn of ~$22.4M/quarter.
Risk Factors
- Massive potential dilution: shelf size ($500M) is 148% of current market cap ($338M)
- Cash runway of only ~2.6 quarters at current burn rate ($22.4M/quarter)
- Pre-revenue clinical-stage company with no approved products and uncertain pipeline timelines
- Historical poor calibration: prior reports on FBRX show avg -10.5% T+20 return and 20% win rate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001193125-26-260329 |
| Document: d117004dex231.htm | 0001193125-26-260329 |
| Document: 0001193125-26-260329-index-headers.html | 0001193125-26-260329 |
| Document: 0001193125-26-260329-index.html | 0001193125-26-260329 |
| Document: 0001193125-26-260329.txt | 0001193125-26-260329 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | EFFECT | $76.99 awaiting T+1 | awaiting T+1 | — | — |
Sep 2, 2026 4w ago | EFFECT | $76.99 awaiting T+1 | awaiting T+1 | — | — |
Aug 27, 2026 5w ago | 25-NSE | $76.99 $76.99 | · 0.00% | ▼ −0.23% | — |
Jul 27, 2026 9w ago | 8-K | $76.50 $76.65 | ▲ +0.20% | ▼ −0.04% | — |
Jun 11, 2026 16w ago | EFFECT | $17.40 $17.56 | ▼ −0.92% | ▼ −0.38% | — |
Jun 6, 2026 16w ago | S-3/A | $15.67 $17.00 | ▼ −8.49% | ▼ −8.78% | — |
Jun 2, 2026 17w ago | S-3 | $17.00 $16.69 | ▲ +1.82% | ▲ +2.22% | — |
Jun 2, 2026 17w ago | 8-K | $17.00 $16.69 | ▼ −1.82% | ▼ −2.23% | — |
May 14, 2026 20w ago | 8-K | $23.11 $20.97 | ▼ −9.26% | ▼ −9.20% | — |
Apr 9, 2026 25w ago | 8-K | $33.90 $35.09 | ▲ +3.51% | ▲ +3.57% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access